Fig. 1

Linagliptin prevents WD-induced diastolic dysfunction. Echocardiographic assessment of cardiac function indicates that WD induces impairments in a E’/A’ tissue Doppler index of diastolic function, b Vp, flow propagation velocity of early mitral inflow; c E/Vp, an index of LV filling pressure; d MPI myocardial performance index of global cardiac function; e IVRT isovolumic relaxation time; and f IVCT isovolumic contraction time. These functional impairments are prevented by administration of linagliptin. *p < 0.05 CD vs WD;^†p < 0.05 WD vs WDL. N = 10/group